The value-based care payment and care delivery model has been evolving for more than a decade, and with the right risk tolerance and aligned incentives, it promises to benefit patients, providers and payers.
“While the adoption has been windy, there are clear signs of VBC’s stickiness and…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
